| |  Online-Ressource |
|---|
| Verfasst von: | Aigner, Julia [VerfasserIn]  |
|---|
| | Bischofs, Esther [VerfasserIn] |
|---|
| | Hallscheidt, Peter [VerfasserIn] |
|---|
| | Sohn, Christof [VerfasserIn] |
|---|
| | Schneeweiss, Andreas [VerfasserIn] |
|---|
| | Eichbaum, Michael H. R. [VerfasserIn] |
|---|
| Titel: | Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment |
|---|
| Verf.angabe: | Julia Aigner, Esther Bischofs, Peter Hallscheidt, Christof Sohn, Andreas Schneeweiss and Michael Eichbaum |
|---|
| Jahr: | 2011 |
|---|
| Umfang: | 4 S. |
|---|
| Fussnoten: | Gesehen am 28.02.2022 |
|---|
| Titel Quelle: | Enthalten in: Anti-cancer drugs |
|---|
| Ort Quelle: | Hagerstown, Md. : Lippincott Williams & Wilkins, 1990 |
|---|
| Jahr Quelle: | 2011 |
|---|
| Band/Heft Quelle: | 22(2011), 10, Seite 1030-1033 |
|---|
| ISSN Quelle: | 1473-5741 |
|---|
| Abstract: | Vascular endothelial growth factor seems to be a promoter of tumor progression for epithelial ovarian cancer. New drugs such as bevacizumab, either alone or in combination with metronomic chemotherapy, suppress tumor growth and have proved to be effective in various tumor types. We present a 60-year-old patient with heavily pretreated, recurrent epithelial ovarian cancer, who received bevacizumab (10 mg/m2) every 2 weeks in combination with metronomic administered low-dose cyclophosphamide (50 mg/day orally) after failing four explorative laparotomies and multiple chemotherapy regimes. At the time of writing, February 2011, she was being treated with this combination therapy for 24 months and the progression-free survival still continues. Treatment of advanced, refractory epithelial ovarian cancer with bevacizumab in combination with low-dose cyclophosphamide could be a very effective salvage treatment option in heavily pretreated patients. |
|---|
| DOI: | doi:10.1097/CAD.0b013e32834a62b4 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1097/CAD.0b013e32834a62b4 |
|---|
| | Volltext: https://journals.lww.com/anti-cancerdrugs/Fulltext/2011/11000/Long_term_remission_in_a_patient_with_heavily.12.aspx |
|---|
| | DOI: https://doi.org/10.1097/CAD.0b013e32834a62b4 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1794037195 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment / Aigner, Julia [VerfasserIn]; 2011 (Online-Ressource)
